Antithrombotic treatment in atrial fibrillation

Kalra, Lalit; Lip, Gregory Y.H.

doi:10.1136/hrt.2006.099911

Cited by 27 publications

(9 citation statements)

References 54 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These patients constituted a large majority of our patient population: 380 patients (67%). Patients with a low or a high risk of stroke are much easier to manage from the antithrombotic point of view: patients at low risk should be treated with aspirin, and those at high risk with warfarin, if not contraindicated 22,23 …”

Section: Discussionmentioning

confidence: 99%

Presence and Duration of Atrial Fibrillation Detected by Continuous Monitoring: Crucial Implications for the Risk of Thromboembolic Events

Botto¹,

Padeletti

Santini

et al. 2009

Cardiovasc electrophysiol

344

248

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Presence and Duration of Atrial Fibrillation Detected by Continuous Monitoring: Crucial Implications for the Risk of Thromboembolic Events

Botto¹,

Padeletti

Santini

et al. 2009

Cardiovasc electrophysiol

344

248

View full text Add to dashboard Cite

show abstract

“…Vitamin K antagonists, most important among which is warfarin, significantly reduce the risk of stroke by almost two-thirds compared to placebo. Owing to the difficulties with using warfarin of its requirement for frequent monitoring of the international normalized ratio (INR) and increased hemorrhagic risk with increased duration of therapy, Aspirin has been considered a potential alternate" [69,[91][92][93]. "Most of the evidence about aspirin therapy's effects among patients with atrial fibrillation was provided by the European atrial fibrillation trial" [69,94].…”

Section: Secondary Prevention For Atrial Fibrillationmentioning

confidence: 99%

Pharmacology, Pharmaceutics and Clinical Use of Aspirin: A Narrative Review

Alegbeleye

Akpoveso

Mohammed

et al. 2020

J. Drug Delivery Ther.

View full text Add to dashboard Cite

Background: Aspirin is one of the most frequently used and cheapest drugs in medicine. Since its first synthesis in 1897, several medicinal roles and mechanisms of action of Aspirin have become apparent, the latest among these being its role in cancer prevention and treatment. Objective: We present a review of Aspirin's biochemistry and pharmacology, as well as the clinical use of Aspirin. The communiqué also suggests possible strategies for maximizing the gain of Aspirin as a wonder-drug of the future. Methods: The literature search strategy covered printed and online sources, including manual library search (PubMed), Embase, Medline, and Cochrane Library. For papers written in English and published in the last ten years. A systematic analysis of available data was subsequently performed based on the review questions. An estimated 155 articles were found online, and twenty-eight articles utilized in the final analysis. Discussion: Aspirin belongs to the non-steroidal anti-inflammatory drugs with a wide range of pharmacological activities, including analgesic, antipyretic, and antiplatelet properties. Discovery of antiplatelet effects led to the increasing use of Aspirin as an anti-thrombotic agent in the prevention of cardiovascular diseases from the 1980s, and firm evidence supporting its usefulness has continued to accumulate. Aspirin irreversibly inhibits platelet function by acetylating cyclooxygenase (COX), which is involved in the production of a potent platelet stimulator, thromboxane A2. The inhibition of COX-2 by Aspirin forms the basis of its anticipated role in preventing colorectal cancer and Alzheimer's disease and the inhibition of the progression of these diseases. It has been pointed out that the incidence of cardiovascular events tends to be high among patients who are Aspirin resistant, but the reason for this increased incidence remains unclear. Conclusion: The emerging future interest is to accrue evidence in favor of Aspirin as the novel therapeutic drug for combating severe acute inflammation and thrombosis associated with the cytokine storm in COVID-19 patients. Notably, a randomized clinical trial, to test a range of potential treatments for COVID-19, includes low-dose Aspirin as anti-inflammatory and antiplatelet treatment. Keywords: Aspirin; Anti-platelet; Nonsteroidal Anti-inflammatory Drug; Pharmaceutic; Pharmacodynamic; Pharmacokinetic.

show abstract

“…53 Older guidelines have divided stroke risk into low, moderate and high-risk categories, whereby high-risk patients could be targeted for warfarin, low-risk patients given aspirin and moderate-risk patients given aspirin or warfarin. 55,56 This was in the era prior to the availability of new OACs with demonstrable efficacy over warfarin, and even better safety (and possibly, tolerability) over aspirin and warfarin, as well as the increasing recognition that aspirin had minimal beneficial impact on stroke prevention and may not be any safer. As mentioned above, the Japanese guidelines have removed aspirin from their stroke prevention guidelines for AF.…”

Section: Stroke Risk Stratificationmentioning

confidence: 99%

What is the most effective and safest delivery of thromboprophylaxis in atrial fibrillation?

Lip

2012

J R Coll Physicians Edinb

View full text Add to dashboard Cite

Antithrombotic treatment in atrial fibrillation

Cited by 27 publications

References 54 publications

Presence and Duration of Atrial Fibrillation Detected by Continuous Monitoring: Crucial Implications for the Risk of Thromboembolic Events

Presence and Duration of Atrial Fibrillation Detected by Continuous Monitoring: Crucial Implications for the Risk of Thromboembolic Events

Pharmacology, Pharmaceutics and Clinical Use of Aspirin: A Narrative Review

What is the most effective and safest delivery of thromboprophylaxis in atrial fibrillation?

Contact Info

Product

Resources

About